FDA has approved two denosumab biosimilars from the Amneal–mAbxience partnership: Boncresa, referencing Prolia for osteoporosis and related uses, and Oziltus, referencing Xgeva for oncology-related bone conditions. mAbxience led development and manufacturing, while Amneal holds exclusive U.S. commercialization rights. The reference brands generated an estimated $5.3 billion in U.S. sales for the 12 months ended October 2025, putting this approval among the year’s most commercially meaningful biosimilar entries.
The strategic question is whether denosumab will become a proving ground for broad, Part B biosimilar adoption beyond oncology mainstays. Unlike adalimumab and other pharmacy-benefit precedents, denosumab is almost entirely buy-and-bill and administered by specialists across oncology, endocrinology, rheumatology, and primary care. That places the economics squarely in the hands of providers and GPOs, with Medicare’s enhanced add-on payment for qualifying biosimilars and aggressive payer medical policies poised to drive uptake if channel frictions are minimized.
For payers, the opportunity is immediate. Prolia’s twice-yearly dosing across a large osteoporosis population and Xgeva’s monthly use in cancer care represent meaningful medical benefit spend that can be redirected if biosimilars launch with compelling net pricing and swift coding. Expect rapid movement toward preferred-product policies, white- or brown-bagging in some regions, and tighter authorization criteria that steer to lowest-net options. For providers, the math will matter as much as the medicine. The ASP-based add-on tied to the reference product improves margins on biosimilars under Medicare, but contract terms, inventory risk, and J-code timing will determine practice behavior. For HCPs, particularly in CKD, oncology, and frailty populations, confidence around switching, calcium/vitamin D management, and adverse event vigilance will define clinical comfort. Medical Affairs teams will need clear education across two distinct channels, coupled with real-world data to reinforce comparability and mitigate nocebo effects.
The competitive context is intensifying. Denosumab attracted multiple developers, and at least one first-wave competitor reached approval earlier, setting an anchor for price erosion and access strategies. Amneal’s asset-light model—with mAbxience supplying and Amneal commercializing—fits a broader trend of U.S. players using global CDMO-backed capabilities to scale biosimilars without building costly biologics infrastructure. Success will hinge on execution details: permanent J-codes secured on schedule, robust HUB and patient support for osteoporosis, oncology-specific pathways and GPO contracting for Oziltus, and field teams that can span two very different prescriber universes. The market could evolve into a segmented race in which oncology access moves fastest via GPO leverage, while osteoporosis adoption follows as large primary and specialty networks update pathways and inventory practices.
This approval also lands amid a payer environment straining under GLP-1 spend and oncology innovation costs, sharpening the appetite for medical-benefit savings. If denosumab biosimilars convert at scale, they may establish a template for future Part B categories where safety monitoring and site-of-care logistics are more complex than in prior biosimilar waves. Watch for three signals over the next two quarters: actual launch timing relative to coding and any residual IP constraints, net price positioning versus the first entrants, and the speed at which large payers and IDNs formalize biosimilar-first policies across both osteoporosis and oncology. The open question is whether denosumab becomes the moment when Part B biosimilars break decisively beyond oncology monocultures—and, if so, who captures the margin: payers via lowest-net mandates, providers via ASP incentives, or manufacturers via disciplined contracting.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
